This study proposes the potential use of [89Zr]-anti-PD-1 immuno-PET as a safe and feasible imaging modality to monitor PD-1/PD-L1 inhibitor antitumor response in NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.